Coronary Artery Disease Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

"DelveInsight's Coronary Artery Disease Pipeline Insight 2022 report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Coronary Artery Disease pipeline landscape"

Coronary Artery Disease pipeline report covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Coronary Artery Disease emerging drugs, the Coronary Artery Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Coronary Artery Disease pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key takeaways from the Coronary Artery Disease Pipeline Report
• DelveInsight's Coronary Artery Disease Pipeline analysis depicts the space with 30+ active players working to develop 30+ pipeline therapies.
• Coronary Artery Disease pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
• Coronary Artery Disease pipeline companies included Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, Novartis Pharmaceuticals, and Several Others
• Coronary Artery Disease Pipeline Therapies included Selatogrel, Atuliflapon, XTR 003, and several others

Get to know more in-depth information about the Coronary Artery Disease Pipeline Report, click here: Coronary Artery Disease Pipeline Insight @ https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Coronary Artery Disease Overview
Coronary artery disease is the most common type of heart disease in the United States. It is sometimes called coronary heart disease or ischemic heart disease. CAD is caused by plaque buildup in the walls of the arteries that supply blood to the heart (called coronary arteries) and other parts of the body.Plaque is made up of deposits of cholesterol and other substances in the artery. Plaque buildup causes the inside of the arteries to narrow over time, which can partially or totally block the blood flow. This process is called atherosclerosis. Angina, or chest pain and discomfort, is the most common symptom of Coronary Artery Disease.

Coronary Artery Disease Pipeline Insight Report
Coronary Artery Disease Pipeline Insight 2022 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Coronary Artery Disease pipeline landscape is provided which includes the disease overview and Coronary Artery Disease treatment guidelines. The assessment part of the report embraces, in depth Coronary Artery Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Coronary Artery Disease Emerging Drugs

Selatogrel: Idorsia Pharmaceuticals
Selatogrel, is a small molecule being developed by Idorsia Pharmaceuticals. It acts as a P2Y12 receptor antagonist. Currently, the drug is being studied in Phase II stage of Clinical trial evaluation for the treatment of Coronary artery disease.

Atuliflapon: AstraZeneca
Atuliflapon (formerly AZD 5718) is an orally available, small molecule, 5-lipoxygenase activating protein inhibitor, being developed by AstraZeneca. Currently, the drug is being studied in Phase II stage of clinical trial evaluation for the treatment of Coronary artery disease.

XTR 003: Sinotau Pharmaceuticals
XTR003 is a PET imaging radiopharmaceutical agent used to trace myocardial fatty acid metabolism. XTR003 is a modified fatty acid that enters the myocytes and passes through mitochondrial membrane by the same process as the natural existing fatty acids and then undergoes partial β-oxidation before being trapped in the mitochondria. In preclinical study XTR003 showed high myocardial uptake and retention. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Coronary Artery Disease.

Coronary Artery Disease Pipeline Therapeutics Analysis
There are approx. 30+ key companies which are developing the therapies for Coronary Artery Disease. The companies which have their Coronary Artery Disease drug candidates in the most advanced stage, i.e. Phase II include, Idorsia Pharmaceuticals.

Coronary Artery Disease Pipeline Phases
DelveInsight's report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

For further information about Coronary Artery Disease treatment and pipeline therapies, visit @ Coronary Artery Disease Pipeline Assessment @ https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Coronary Artery Disease Pipeline Analysis
The report provides insights into:
• The Coronary Artery Disease report provides detailed insights about companies that are developing therapies for the treatment of Coronary Artery Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Coronary Artery Disease Treatment.
• Coronary Artery Disease key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Coronary Artery Disease Drugs are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Coronary Artery Disease market.

The Coronary Artery Disease report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Scope of the Coronary Artery Disease Pipeline Report
• Coverage- Global
• Coronary Artery Disease pipeline companies included Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, Novartis Pharmaceuticals, and Several Others
• Coronary Artery Disease Pipeline Therapies included Selatogrel, Atuliflapon, XTR 003, and several others
• Coronary Artery Disease Preclinical and Discovery Stage Products
• Coronary Artery Disease Inactive Products

Table of content
1. Introduction
2. Coronary Artery Disease Coronary Executive Summary
3. Coronary Artery Disease: Overview
4. Coronary Artery Disease Coronary Pipeline Therapeutics
5. Coronary Artery Disease Coronary Therapeutic Assessment
6. Coronary Artery Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Mid Stage Products (Phase II)
10. Selatogrel: Idorsia Pharmaceuticals
11. Early Stage Products (Phase I)
12. XTR 003: Sinotau Pharmaceuticals
13. Preclinical and Discovery Stage Products
14. Drug name: Company Name
15. Inactive Products
16. Coronary Artery Disease Key Companies
17. Coronary Artery Disease Key Products
18. Coronary Artery Disease- Unmet Needs
19. Coronary Artery Disease- Market Drivers and Barriers
20. Coronary Artery Disease- Future Perspectives and Conclusion
21. Coronary Artery Disease Analyst Views
22. Coronary Artery Disease Key Companies
23. Appendix

Got Queries? Reach out for more information @ Coronary Artery Disease Clinical Trials @ https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.